Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Discovery of 2-[1-(4,4-Difluorocyclohexyl)piperidin-4-yl]-6-fluoro-3-oxo-2,3-dihydro-1H-isoindole-4-carboxamide (NMS-P118): A Potent, Orally Available, and Highly Selective PARP-1 Inhibitor for Cancer Therapy
Gianluca Papeo, Helena Posteri, Daniela Borghi, et al.
Journal of Medicinal Chemistry (2015) Vol. 58, Iss. 17, pp. 6875-6898
Closed Access | Times Cited: 121

Showing 1-25 of 121 citing articles:

DNA repair targeted therapy: The past or future of cancer treatment?
Navnath S. Gavande, Pamela S. VanderVere-Carozza, Hilary D. Hinshaw, et al.
Pharmacology & Therapeutics (2016) Vol. 160, pp. 65-83
Open Access | Times Cited: 340
Structural Basis for Potency and Promiscuity in Poly(ADP-ribose) Polymerase (PARP) and Tankyrase Inhibitors
A.G. Thorsell, T. Ekblad, T. Karlberg, et al.
Journal of Medicinal Chemistry (2016) Vol. 60, Iss. 4, pp. 1262-1271
Open Access | Times Cited: 330
An Update on Poly(ADP-ribose)polymerase-1 (PARP-1) Inhibitors: Opportunities and Challenges in Cancer Therapy
Ying-Qing Wang, Pingyuan Wang, Yu-Ting Wang, et al.
Journal of Medicinal Chemistry (2016) Vol. 59, Iss. 21, pp. 9575-9598
Closed Access | Times Cited: 201
A new wave of innovations within the DNA damage response
Qi Li, Wenyuan Qian, Yang Zhang, et al.
Signal Transduction and Targeted Therapy (2023) Vol. 8, Iss. 1
Open Access | Times Cited: 56
New Horizons of Synthetic Lethality in Cancer: Current Development and Future Perspectives
Viola Previtali, Greta Bagnolini, Andrea Ciamarone, et al.
Journal of Medicinal Chemistry (2024) Vol. 67, Iss. 14, pp. 11488-11521
Open Access | Times Cited: 17
Discovery and Characterization of (8S,9R)-5-Fluoro-8-(4-fluorophenyl)-9-(1-methyl-1H-1,2,4-triazol-5-yl)-2,7,8,9-tetrahydro-3H-pyrido[4,3,2-de]phthalazin-3-one (BMN 673, Talazoparib), a Novel, Highly Potent, and Orally Efficacious Poly(ADP-ribose) Polymerase-1/2 Inhibitor, as an Anticancer Agent
Bing Wang, Daniel I. Chu, Ying Feng, et al.
Journal of Medicinal Chemistry (2015) Vol. 59, Iss. 1, pp. 335-357
Closed Access | Times Cited: 151
AutoGrow4: an open-source genetic algorithm for de novo drug design and lead optimization
Jacob O. Spiegel, Jacob D. Durrant
Journal of Cheminformatics (2020) Vol. 12, Iss. 1
Open Access | Times Cited: 134
Medicinal chemistry approaches of poly ADP-Ribose polymerase 1 (PARP1) inhibitors as anticancer agents - A recent update
Priyancy G. Jain, Bhumika Patel
European Journal of Medicinal Chemistry (2019) Vol. 165, pp. 198-215
Closed Access | Times Cited: 116
PARP Trapping Beyond Homologous Recombination and Platinum Sensitivity in Cancers
Junko Murai, Yves Pommier
Annual Review of Cancer Biology (2018) Vol. 3, Iss. 1, pp. 131-150
Closed Access | Times Cited: 96
Emerging Building Blocks for Medicinal Chemistry: Recent Synthetic Advances
Oleksandr O. Grygorenko, Dmitriy M. Volochnyuk, Bohdan V. Vashchenko
European Journal of Organic Chemistry (2021) Vol. 2021, Iss. 47, pp. 6478-6510
Closed Access | Times Cited: 95
Discovery of 5-{4-[(7-Ethyl-6-oxo-5,6-dihydro-1,5-naphthyridin-3-yl)methyl]piperazin-1-yl}-N-methylpyridine-2-carboxamide (AZD5305): A PARP1–DNA Trapper with High Selectivity for PARP1 over PARP2 and Other PARPs
Jeffrey W. Johannes, Amber Balazs, Derek Barratt, et al.
Journal of Medicinal Chemistry (2021) Vol. 64, Iss. 19, pp. 14498-14512
Closed Access | Times Cited: 90
Autonomous molecule generation using reinforcement learning and docking to develop potential novel inhibitors
Woosung Jeon, Dongsup Kim
Scientific Reports (2020) Vol. 10, Iss. 1
Open Access | Times Cited: 72
PARP Power: A Structural Perspective on PARP1, PARP2, and PARP3 in DNA Damage Repair and Nucleosome Remodelling
Lotte van Beek, Éilís McClay, Saleha Patel, et al.
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 10, pp. 5112-5112
Open Access | Times Cited: 68
PARP1: Structural insights and pharmacological targets for inhibition
Jacob O. Spiegel, Bennett Van Houten, Jacob D. Durrant
DNA repair (2021) Vol. 103, pp. 103125-103125
Open Access | Times Cited: 63
Fluorinated Cycloalkyl Building Blocks for Drug Discovery
Oleksandr O. Grygorenko, Kostiantyn P. Melnykov, Serhii Holovach, et al.
ChemMedChem (2022) Vol. 17, Iss. 21
Closed Access | Times Cited: 57
Mechanism of PARP inhibitor resistance and potential overcoming strategies
Xiaoyu Fu, Ping Li, Qi Zhou, et al.
Genes & Diseases (2023) Vol. 11, Iss. 1, pp. 306-320
Open Access | Times Cited: 29
The PARP Inhibitor AZD2461 Provides Insights into the Role of PARP3 Inhibition for Both Synthetic Lethality and Tolerability with Chemotherapy in Preclinical Models
Lenka Oplustil O’Connor, Stuart L. Rulten, Aaron Cranston, et al.
Cancer Research (2016) Vol. 76, Iss. 20, pp. 6084-6094
Open Access | Times Cited: 82
Olaparib hydroxamic acid derivatives as dual PARP and HDAC inhibitors for cancer therapy
Zigao Yuan, Shaopeng Chen, Qinsheng Sun, et al.
Bioorganic & Medicinal Chemistry (2017) Vol. 25, Iss. 15, pp. 4100-4109
Closed Access | Times Cited: 77
Objective, Quantitative, Data-Driven Assessment of Chemical Probes
Albert A. Antolín, Joseph E Tym, Angeliki Komianou, et al.
Cell chemical biology (2017) Vol. 25, Iss. 2, pp. 194-205.e5
Open Access | Times Cited: 77
Efficient route for the construction of polycyclic systems from bioderived HMF
Fedor A. Kucherov, Konstantin I. Galkin, Evgeniy G. Gordeev, et al.
Green Chemistry (2017) Vol. 19, Iss. 20, pp. 4858-4864
Open Access | Times Cited: 70
Discovery of Novel Bromophenol–Thiosemicarbazone Hybrids as Potent Selective Inhibitors of Poly(ADP-ribose) Polymerase-1 (PARP-1) for Use in Cancer
Chuanlong Guo, Lijun Wang, Xiuxue Li, et al.
Journal of Medicinal Chemistry (2019) Vol. 62, Iss. 6, pp. 3051-3067
Closed Access | Times Cited: 68
Discovery of novel functionalized 1,2,4-triazoles as PARP-1 inhibitors in breast cancer: Design, synthesis and antitumor activity evaluation
Ahmed T. A. Boraei, Pankaj Kumar Singh, Mario Sechi, et al.
European Journal of Medicinal Chemistry (2019) Vol. 182, pp. 111621-111621
Closed Access | Times Cited: 62
Discovery of SK-575 as a Highly Potent and Efficacious Proteolysis-Targeting Chimera Degrader of PARP1 for Treating Cancers
Chao-Guo Cao, Jie Yang, Yong Chen, et al.
Journal of Medicinal Chemistry (2020) Vol. 63, Iss. 19, pp. 11012-11033
Closed Access | Times Cited: 61
The ups and downs of Poly(ADP-ribose) Polymerase-1 inhibitors in cancer therapy–Current progress and future direction
Yue Zhao, Liu‐Xia Zhang, Ting Jiang, et al.
European Journal of Medicinal Chemistry (2020) Vol. 203, pp. 112570-112570
Closed Access | Times Cited: 60
Discovery of Pamiparib (BGB-290), a Potent and Selective Poly (ADP-ribose) Polymerase (PARP) Inhibitor in Clinical Development
Hexiang Wang, Bo Ren, Ye Liu, et al.
Journal of Medicinal Chemistry (2020) Vol. 63, Iss. 24, pp. 15541-15563
Closed Access | Times Cited: 57
Page 1 - Next Page

Scroll to top